Figure 7: GALNT14 mediates macrophage-stimulated BCC growth in the lung parenchyma via activation of FGF signalling.

(a,b) Comparison of macrophage-stimulated growth of the indicated 231-LM2 (a) and CN34-LM1 (b) cells in the absence or presence of pan-FGFR inhibitor BGJ398 (100 nM) or FGFR1/3-specific inhibitor PD173074 (100 nM). The inhibitors were treated for 12 h before co-culture and relative cell growth was analysed after 3 days. n=6. (c) The indicated 231-LM2 cells were cultured in the absence or presence of RAW 264.7 cells with or without PD173074 and the phosphorylation of ERK1/2 and AKT was analysed. (d) 231-LM2 cells, transfected with scrambled or two independent siRNAs against FGFR1 or FGFR3, were grown in the absence or presence of RAW 264.7 and their relative growth rates were analysed. n=6. (e) O-glycosylation of endogenous FGF receptor 1. Lysates from the indicated 231-LM2 cells were subjected to VVA pull-down assays as in Fig. 4f, followed by the western blot analyses with FGFR1 and FGFR3 antibodies. 1 mM benzyl-GalNAc was added to the media 24 h before pull-down where indicated. (f) The indicated 231-LM2 cells were co-cultured with RAW 264.7 cells expressing scrambled siRNA (siScr) or two independent siFgf2 RNAs and the relative growth of 231-LM2 cells were analysed. n=6. P values were calculated using two-tailed unpaired Student’s t-test. Data are mean±s.e.m. Western blot images in c,e are representative of three independent experiments.